These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26261064)

  • 1. Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions.
    Pignatti F; Ashby D; Brass EP; Eichler HG; Frey P; Hillege HL; Hori A; Levitan B; Liberti L; Löfstedt RE; McAuslane N; Micaleff A; Noel RA; Postmus D; Renn O; Sabourin BJ; Salmonson T; Walker S
    Clin Pharmacol Ther; 2015 Nov; 98(5):522-33. PubMed ID: 26261064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structured Benefit-risk assessment: a review of key publications and initiatives on frameworks and methodologies.
    Mt-Isa S; Ouwens M; Robert V; Gebel M; Schacht A; Hirsch I
    Pharm Stat; 2016 Jul; 15(4):324-32. PubMed ID: 25981683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.
    Leong J; McAuslane N; Walker S; Salek S
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):1004-12. PubMed ID: 23740622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports?
    Bujar M; Ferragu S; McAuslane N; Liberti L; Kühler TC
    Clin Ther; 2021 May; 43(5):888-905. PubMed ID: 33883070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review and critique of the Institute of Medicine report "the future of drug safety".
    Benet LZ
    Clin Pharmacol Ther; 2007 Feb; 81(2):158-61. PubMed ID: 17259941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transatlantic regulatory cooperation expanded.
    Hughes B
    Nat Rev Drug Discov; 2007 Aug; 6(8):589-90. PubMed ID: 17821826
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical Benefit-Risk Communication Tools: A Review of the Literature.
    Way D; Blazsin H; Löfstedt R; Bouder F
    Drug Saf; 2017 Jan; 40(1):15-36. PubMed ID: 27743334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of drug safety.
    Breckenridge A
    Clin Pharmacol Ther; 2007 Feb; 81(2):161-3. PubMed ID: 17259942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist.
    Radawski C; Morrato E; Hornbuckle K; Bahri P; Smith M; Juhaeri J; Mol P; Levitan B; Huang HY; Coplan P; Li H;
    Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1233-40. PubMed ID: 26456379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity in Clinical Practice and Drug Development: When is it Significant?
    Shakhnovich V; Meibohm B; Rosenberg A; Kierzek AM; Hasenkamp R; Funk RS; Thalhauser CJ; van der Graaf PH; Wang YC; Hamuro L
    Clin Transl Sci; 2020 Mar; 13(2):219-223. PubMed ID: 31762152
    [No Abstract]   [Full Text] [Related]  

  • 13. [Risk/Benefit Communication: International Developments and Prospects for the Future].
    Yamamoto M
    Yakugaku Zasshi; 2018; 138(3):299-306. PubMed ID: 29503420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.
    Mt-Isa S; Hallgreen CE; Wang N; Callréus T; Genov G; Hirsch I; Hobbiger SF; Hockley KS; Luciani D; Phillips LD; Quartey G; Sarac SB; Stoeckert I; Tzoulaki I; Micaleff A; Ashby D;
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):667-78. PubMed ID: 24821575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European Medicines Agency--more transparency needed.
    Lancet; 2010 May; 375(9728):1753. PubMed ID: 20494710
    [No Abstract]   [Full Text] [Related]  

  • 17. ICCVAM evaluation of the murine local lymph node assay. The ICCVAM review process.
    Sailstad DM; Hattan D; Hill RN; Stokes WS
    Regul Toxicol Pharmacol; 2001 Dec; 34(3):249-57. PubMed ID: 11754529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.